Muscle relaxants linked with increased risk of breathing problems after surgery

October 16, 2012

Muscle relaxants given to millions of patients during general anaesthesia are associated with an increased risk of serious breathing problems after surgery, finds a study published in BMJ today.

The results also suggest that giving drugs to reverse the muscle relaxants after surgery may increase the risk further.

But an accompanying editorial argues that, in , is an extremely safe procedure and it would be a mistake to change clinical practice on the basis of this one study, however large and well executed.

Known as intermediate acting neuromuscular blocking agents, these drugs work by temporarily blocking to muscles. They decrease the need for deep anaesthesia allowing faster recovery after surgery.

When they were first introduced 70 years ago, these blocking agents revolutionised surgical care, but in the 1950s, concerns were raised that they could linger in the body after surgery, causing partial paralysis of the muscles needed for breathing, and putting patients at risk of respiratory complications.

As a result, anaesthetists are now advised to carefully measure the effects of these drugs throughout surgery and to give a drug to reverse the effects at the end of surgery. Subjective is most often used by the without any being made, however.

To address these concerns, an international team of researchers compared outcomes for 18,579 patients who received at least one intermediate acting neuromuscular blocking agent during surgery with the same number of patients who did not.

They found that , such as deteriorating (desaturation) and the need for re- after surgery (a tube inserted into the throat and airway to aid breathing) were more common if a muscle relaxant and a reversal agent had been given, particularly for shorter operations.

Although unusual, re-intubation after surgery often requires admission to an intensive care unit and help with breathing (mechanical ventilation), which is expensive and translates into a higher (but still very low) risk of dying in hospital, explain the authors.

Subjective monitoring during surgery did not significantly modify the risk.

The authors point out that they did not assess the effects of measuring muscle response during surgery in their trial, which may explain some of their findings. But they, like many other experts, believe that subjective monitoring should be replaced by specific measurements throughout an operation. This would give doctors real (objective) numbers to help them compare patient outcomes against a standard model of care.

However, they say their results suggest that neuromuscular blocking agents may be an independent risk factor for severe respiratory events in the first few days after surgery. "Strategies to prevent residual postoperative neuromuscular blockade should be revisited," they conclude.

In an accompanying editorial, Jennifer Hunter, Emeritus Professor of Anaesthesia at the University of Liverpool, says the study is timely, but she expresses concern that, in light of current available evidence, "it would seem wise to continue to use quantitative neuromuscular monitoring, intermediate acting neuromuscular blocking agents, and a reversal agent unless full recovery of neuromuscular function has been adequately demonstrated."

Explore further: Review of multilevel surgery in patients with obstructive sleep apnea

More information: Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study, BMJ, 2012.

Editorial: Antagonising neuromuscular block at the end of surgery, BMJ, 2012.

Related Stories

Review of multilevel surgery in patients with obstructive sleep apnea

March 19, 2012
Patients with obstructive sleep apnea who undergo surgery for their condition should be closely monitored after their procedures are performed but may not need to be in an intensive care unit, according to a report published ...

Postoperative program prevents respiratory complications: study

October 4, 2012
(HealthDay)—A simple and inexpensive program can reduce the risk of life-threatening and costly respiratory complications that are common after surgery, according to a new study.

Anaesthetic linked to learning problems in children

August 28, 2012
(Medical Xpress)—Children who are given anaesthetic before the age of three may have an increased risk of developing learning difficulties, according to a new study involving researchers at The University of Western Australia.

InteguSeal does not reduce scoliosis surgery infections

July 26, 2012
(HealthDay) -- Preoperative cyanoacrylate sealant (InteguSeal) application does not reduce the risk of surgical site infection for patients undergoing scoliosis surgery, according to a study published online July 18 in Spine.

Tight blood sugar control for pediatric cardiac surgery patients does not improve outcomes

September 10, 2012
Tight blood sugar control in the intensive care unit for pediatric cardiac surgery patients does not improve patients' infection rate, mortality, length of stay or organ failure when compared to standard care, new research ...

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.